LAS VEGAS, Dec. 16, 2024 /PRNewswire/ — CTLA-4 inhibitors are a well-established market in cancer care, and they are expected to grow significantly in the coming years. This is due to the expected label expansion and usage of the blockbuster YERVOY and an increasing number of new…